iii Abstract ADD392124 was identified by the Anticonvulsant Screening Program as being able to control benzodiazepine-resistant lithium-pilocarpine-induced status epilepticus seizures, a seizure model that closely resembles nerve agent-induced seizures. The present research evaluated the ability of ADD392124, delivered as an adjunct to standard antidotes, to control seizures induced by the nerve agent soman when treatment was delayed for 5 or 20 min after seizure onset. Rats, previously prepared with electrodes to record electroencephalographic (EEG) activity, were exposed to a convulsant dose of the nerve agent soman. Seizures were allowed to develop, and the standard treatment for nerve agent intoxication-atropine, 2-PAM (an oxime cholinesterase reactivator), and diazepam (a benzodiazepine)-was administered at either 5 or 20 min after seizures started. This standard treatment alone was unable to stop seizure activity. ADD392124 was administered along with these standard treatments at various doses to determine effective doses for termination of these seizures. ADD392124 was capable of stopping soman-induced seizures at both treatment delay times. The ED 50 for seizure control at the 5-min treatment delay was calculated by probit analysis to be 256.1 mg/kg (226.3 -336.9 mg/kg, 95% confidence limits), while the ED 50 dose for the 20-min treatment delay was 325.7 mg/kg (291.3 -937.5 mg/kg, 95% confidence limits). The time for seizure termination following administration of ADD392124 at the 5-min treatment delay time was 533.9 sec (8.9 min), while the latency for seizure termination at the 20-min delay was 2258.3 sec (37.6 min). As with other anticonvulsant treatments that have been studied in this model, animals in which the seizures were terminated by ADD392124 displayed minimal or no neuropathology, while animals in which the treatment was unsuccessful in stopping the seizures displayed significant levels of neuropathology in those brain areas susceptible to nerve agent-induced damage. In comparison to other drugs that have been studied using this model, ADD392124 was less potent as an anticonvulsant when compared to anticholinergics, N-methyl-d-aspartate (NMDA) antagonists and drugs that enhance gamma-amino butyric acid (GABA) receptor activity. Nevertheless, ADD392124 was successful in terminating soman-induced seizures at delay times (e.g., 20 min) where few other classes of anticonvulsant drugs have proven effective.
Background
Nerve agents are organophosphorous compounds that irreversibly inhibit the enzyme acetylcholinesterase. This leads to a rapid accumulation of the neurotransmitter acetylcholine and an overstimulation of cholinergic effector sites in the brain and periphery. A notable sign of nerve agent poisoning is the development of prolonged status epilepticus seizures (McDonough et al., 1995; McDonough and Shih, 1997) . Nerve agent-induced seizures result from overstimulation of susceptible brain circuits by abnormally high levels of the excitatory neurotransmitter acetylcholine that rapidly builds up after inhibition of the enzyme acetylcholinesterase by nerve agent (McDonough and Shih, 1997) . These seizures, unless quickly stopped pharmacologically, rapidly progress to status epilepticus, a state of continuous seizure activity or episodes of seizure activity for greater than 30 min with no recovery of consciousness between episodes. Status epilepticus itself is considered a medical emergency, and the longer seizures persist the more difficult they are to stop pharmacologically (Shorvon, 1994) .
Status epilepticus clinically responds (n.b., termination of seizures) only to a subset of anticonvulsant or antiepileptic drugs. Benzodiazepines are typically the most effective class of compounds and are used as the drug of first choice in treatment of this condition clinically. Benzodiazepines, barbiturates and compounds with N-methyl-d-aspartate (NMDA) antagonist activity (e.g., ketamine, MK-801), as well as potent anticholinergic compounds, are the only compounds that have been shown to be effective against nerve agent-induced status epilepticus seizures. In addition, like status epilepticus seizures elicited by other means, nerve agentinduced seizures become refractory to treatment with benzodiazepines and anticholinergic drugs the longer treatment is delayed Shih, 1993, 1997; McDonough et al., 2010; Shih et al., 2003 Shih et al., , 2007 .
The present series of experiments were performed to evaluate the anticonvulsant potential of the drug ADD392124. This drug was identified as being effective in terminating benzodiazepine-resistant status epilepticus seizures elicited by lithium-pilocarpine in a rat model utilized by the Anticonvulsant Screening Program (ASP) run at The University of Utah and sponsored by the NINDS. Seizures elicited in the lithium-pilocarpine model have many electroencephalographic (EEG) and pharmacological characteristics that are similar to nerve agent-induced seizures. Following the positive tests in the ASP, a material transfer agreement (MTA) was prepared between the developer of ADD392124 and the US Army Medical Research Institute of Chemical Defense (USAMRICD). This allowed the transfer of a sample of ADD392124 to USAMRICD for testing in a rat model of nerve agent-induced seizures that was developed with the support of an Inter-Agency Agreement between NIH/NINDS and USAMRICD. This rat model was initially developed in the late 1980s Shih et al., 1991) , and variants of this model have been used to test the effectiveness of anticonvulsant compounds from a variety of pharmacological classes for the treatment of nerve agent-induced seizures (McDonough and Shih, 1993; Shih et al., 1999) .
Methods
Subjects: Male Sprague-Dawley rats (Crl:DCBR VAF/Plus) from Charles River Labs, weighing 250-300 g upon receipt, served as subjects. The animals were housed individually in temperature (21+ 2 0 C) and humidity (50 + 10%) controlled quarters and maintained on a 12-h light-dark full spectrum lighting cycle with lights on at 0600. Laboratory rat chow and tap water were freely available.
Surgery: Each animal was anesthetized with isoflurane (5% induction; 3-1.5% maintenance, with oxygen) and placed in a stereotaxic instrument. Two stainless steel screws were placed in the skull bilaterally midway between bregma and lamda and ~3 mm lateral to the midline. A third screw was placed over the cerebellum. The screws were connected to a miniature connector with wires and the screws, wires and connector were then anchored to the skull with dental cement. The incision was sutured; the animal was removed from the frame, given the analgesic buprenorphine HCl (0.03 mg/kg, SC) and placed on a warming pad for at least 30 min before being returned to the animal quarters. Approximately seven days elapsed between surgery and experimentation. . HI-6 (250 mg/ml), atropine methyl nitrate (4.0 mg/ml), atropine sulfate (0.2 mg/ml) admixed with 2-PAM (50.0 mg/ml) and soman (360 μg/ml) were prepared in saline, either fresh daily (HI-6, atropine methyl nitrate, atropine sulfate + 2-PAM) or as frozen aliquots (soman). ADD392124 was received and maintained at room temperature in a dessicator until use. ADD392124 was prepared in 0.5% methyl cellulose fresh each experimental day at concentrations to deliver volumes = 2.0 ml/kg. Because of the poor solubility of ADD392124 in aqueous solutions, limited studies used DMSO and a DMSO (15%) + polyethylene glycol (PEG; 75%) mixture as vehicles.
Anticonvulsant Test: Animals were typically tested in squads of eight on a given study day. The animals were randomized among treatment groups each test day. The animals were weighed, placed in individual recording chambers and connected to the recording apparatus. EEG signals were recorded using CDE 1902 amplifiers and displayed on a computer running Spike2 software (Cambridge Electronic Design, Ltd., Cambridge, UK). Baseline EEG was recorded for at least 20 min. The animals were then pretreated with 125 mg/kg, IP, of the oxime HI-6 to prevent the rapid lethal effects of the soman challenge. Thirty min later the animals were challenged with 180 μg/kg, SC, soman (1.6 X LD 50 ) and 1 min later treated with 2.0 mg/kg, IM, atropine methyl nitrate to minimize peripheral secretions. The animals were then closely monitored both visually and on the EEG for seizure onset. Seizure onset was operationally defined as the appearance of >10 sec of rhythmic high amplitude spikes or sharp waves that were at least twice the baseline amplitude accompanied by a rhythmic bilateral flicking of the ears, facial clonus and possibly forepaw clonus. At 5 or 20 min after seizure onset, the animals received standard medical countermeasures: 0.1 mg/kg atropine sulfate + 25 mg/kg 2-PAM Cl admixed to deliver 0.5 ml/kg, IM, and 0.4 mg/kg, IM, diazepam. These standard medical countermeasures are not sufficient, by themselves, to terminate soman-induced seizures. Immediately after administering the standard medical countermeasures, individual animals received an IP dose of ADD392124 (see Table 1 for doses used). The animals were monitored on the EEG for at least 5 hr after exposure and then returned to the animal housing room. Twenty-four hr after the exposure, the surviving animals were weighed and the EEG again recorded for at least 30 min. Following this, the animals were administered an anesthetic dose (75 mg/kg, IP) of pentobarbital and when deeply anesthetized were perfused intracardially with saline followed by formalin. The brain was harvested, blocked in the coronal plane at the level of the infindibulum and then embedded in paraffin. This insures that nearly identical brain areas are examined from animal to animal. Sections were cut 6-10 μm thick and stained with hematoxylin and eosin. Eight brain areas (dorsal and lateral cerebral cortex, pyriform cortex, amygdala, hippocampus -CA1, CA4/dentate hillus, CA2/CA3, thalamus) were evaluated in each animal using a 0-4 rating scale ( based on the percentage tissue involvement) and then summed to obtain a total neuropathology score. Evaluation and categorization of the EEG response by an individual animal to treatment were performed by a technician and investigator, both well-experienced with the appearance of nerve agent-induced EEG seizure activity. The overall rating and timing of different events required consensus between both individuals, who were aware of the treatment conditions of an individual animal. To be rated as having the seizure terminated, all spiking and/or rhythmic waves had to stop and the EEG had to remain normal at all subsequent observation times (n.b., throughout the 5-hr record following exposure and for the 30-min record 24 hr later). For each animal in which the seizure was terminated, the latency to seizure termination was measured as the time from when the animal received the ADD392124 treatment to the last observable epileptiform event in the EEG.
Data Analysis: The median effective dose for anticonvulsant activity was determined by probit analysis (Bliss, 1952) . Seizure termination latencies were calculated from the time ADD392124 was administered to the termination of EEG spiking and/or rhythmic waves and were evaluated using t-tests; incidence and severity of neuropathology were evaluated with Fisher's exact test and a one-way ANOVA, respectively. In all cases, p<0.05 was considered significant.
Results Table 1 displays the doses used, the numbers of animals tested at each treatment delay time, the fractional response and the percentage of animals displaying an anticonvulsant response. At the 5-min treatment delay time, ADD392124 produced a significant anticonvulsant effect with an ED 50 = 256 mg/kg (226-337 mg/kg = 95% confidence limits). The idealized dose-effect curve for these data is displayed in Figure 1 , and a copy of the probit analysis output is included as Appendix 1. There were five animals, 1 at 140 mg/kg, 2 at 180 mg/kg and 2 at 225 mg/kg ADD392124, that had an initial anticonvulsant response to the treatment and then the seizures returned at a later time; these animals were considered treatment failures. There were also two animals at the 280 mg/kg dose that had their seizures terminated, but failed to survive 24 hr; these animals were considered treatment successes. The average latency for seizure termination at the 5-min treatment delay time was 534 sec (8.9 min) (196 -871 sec = 95% confidence limits), and this is displayed graphically in Figure 2 .
At the 20-min treatment delay time, ADD392124 failed to produce a statistically significant anticonvulsant effect due to the low number of responders in the 320 mg/kg treatment group. Because of this, while an anticonvulsant ED 50 could be calculated by probit analysis (20-min delay anticonvulsant ED 50 = 321 mg/kg ADD392124), no confidence limits could be determined. The idealized dose-effect curve for these data is displayed in Figure 1 , and a copy of the probit analysis output is included as Appendix 2. As mentioned in the methods, DMSO and DMSO + PEG were also used as solvents in a limited number of animals (DMSO = 5; DMSO + PEG = 4) at the 320 mg/kg dose. These solvents produced about the same response rate as when ADD392124 was used in 0.5% methyl cellulose. Specifically, a 2 of 5 response rate for DMSO and a 2 of 4 response rate for DMSO + PEG. When all the solvents for the 320 mg/kg dose of ADD392124 were factored into a probit analysis, it resulted in a significant result with an ED 50 = 326 mg/kg (291 -938 mg/kg = 95% confidence limits), a dose comparable to that obtained with just the methyl cellulose vehicle animals alone. The dose-effect curve for this result is presented in Figure 3 . The copy of this probit analysis output is included as Appendix 3. As at the 5 min test, there were five animals, 3 at 225 mg/kg and 2 at 320 mg/kg, that had an initial anticonvulsant response to the treatment and then the seizures returned at a later time; these animals were considered treatment failures. There were also two animals, one each at the 180 and the 280 mg/kg doses that had their seizures terminated, but failed to survive 24 hr; these animals were considered treatment successes. The average latency for seizure termination at the 20-min treatment delay time was 2258 sec (37.6 min) (1091 -3426 sec = 95% confidence limits) and this is displayed graphically in Figure 2 . The latency for seizure control at the 20-min treatment delay time was significantly (t = 3.52, df = 39, p < 0.01) longer than the comparable latency at the 5-min treatment delay time.
Brains were examined microscopically for evidence of neuropathology. As observed in other studies, evidence of neuropathology was strongly related to the ability of the test drug to control seizure activity. Table 2 displays the numbers of animals that either did or did not display neuropathology when animals were classified as Treatment Success vs Treatment Failure. As can be seen from the table, animals classified as Treatment Failures overwhelmingly displayed neuropathology when compared to animals classified as Treatment Successes. A Fisher's exact test confirmed this impression, and showed a highly significant (p < 0.001) difference between groups. Of the seven animals in the Treatment Success/Neuropathology classification, six of them were treated at the 20 min treatment delay time. Animals in the Treatment Success/ Neuropathology classification had significantly (t = 4.50, df = 46, p < 0.001) lower total neuropathology scores (X = 1.7) when compared to the total neuropathology scores of the animals in the Treatment Failure/Neuropathology classification (X = 12.10). These data all show that successful anticonvulsant action by ADD392124 either totally prevented or significantly minimized the brain pathology in surviving animals. Note: data collapsed across both treatment delay times. Both the incidence (Fisher's exact test, p < 0.01) and severity of neuropathology (t test, p < 0.01) were significantly influenced by treatment success or failure.
Discussion
ADD392124 was effective in terminating status epilepticus seizures elicited by the nerve agent soman in rats when treatment was delivered either at 5 or 20 min following seizure onset. As with other compounds tested with this animal model, higher drug doses were required to terminate seizures and it took the seizures longer to stop at the 20-min treatment delay than at the 5-min treatment delay. Successful anticonvulsant treatment was also associated with the prevention or significant reduction of brain pathology produced by the seizures. The ED 50 s for this anticonvulsant effect were 256 and 326 mg/kg for the 5-and the 20-min treatment delay times, respectively. The fact that a higher dose of ADD392124 was required at the 20-min treatment delay time is a common finding with this animal model with either anticholinergic drugs or benzodiazepines (McDonough and Shih, 1993; Shih et al., 1999) . However, it is notable that the shift in ED 50 s for these other compounds (anticholinergics or benzodiazepines) is of a substantially greater magnitude, on the order of 0.5 -1.0 log unit, while the shift in the curves for ADD392124 was only ~0.1 log unit. Thus, while ADD392124 may be substantially less potent on a mg basis when compared to other compounds that can control nerve agent seizures, it does differ in the fact that it retains potency at longer treatment delays.
The time for seizure control seen at the 5-min treatment delay time, 8.9 min, is comparable to the times it takes anticholinergics or benzodiazepines to control soman-induced seizures under these conditions (McDonough and Shih, 1993; Shih et al., 1999) . Also, the increase in the latencies for seizure control with longer treatment delays (e.g., 20 min) is commonly observed with other drugs in this model, so the fact that this was observed with ADD392124 should not be considered unusual.
Control of soman-induced seizures with ADD392124 successfully protected animals against the severe neuropathology that is typically observed in the brains of animals exposed to nerve agents (Carpentier et al., 1990; McDonough et al., 1995) . Some of the successfully treated 20-min treatment delay animals developed minimal amounts of neuropathology. This has been observed in other experiments, and it has been concluded that as little as 20 min of intense seizure activity will already have set up a pathological process in vulnerable neurons that will be observed histopathologically when the animal is euthanized 24 hr later (Lallement et al., 1994; McDonough et al., 1995) . The fact that the pathology scores of this treatment success group were significantly lower than the animals in which seizures were not stopped shows how important control of seizure activity is to this process.
ADD392124 proved difficult to put into solution. While it suspended well in 0.5% methyl cellulose, injection IP into an animal using anything <18 gage needle proved problematic. Other solvents were tested, but this was limited due to the small amount of test compound available. ADD392124 did dissolve in DMSO and also could be dissolved in limited amounts of DMSO and then diluted to a final concentration with PEG. Both of these formulations appeared to have the same potency as when 0.5% methyl cellulose was used. Formulations of ADD392124 or analogs of this compound that dissolved in more aqueous solutions may have a more potent and rapid anticonvulsant effect.
In summary, ADD392124 provided effective anticonvulsant action against seizures induced in rats by the nerve agent soman when it was administered at 5 or 20 min after seizure onset. As with other compounds tested with this animal model, higher drug doses were required to terminate seizures, and it took the seizures longer to stop at the 20-min treatment delay than at the 5-min treatment delay. Successful anticonvulsant action with ADD392124 was able to prevent or minimize seizure-induced brain pathology, another result that is commonly seen in this model. It is speculated that improved formulations of ADD392124 may enhance the anticonvulsant effect. 
